Ramona participated a phase I study on the safety of the new biologic agent CTLA4-Ig given in conjunction with maintenance cyclophosphamide, where she received a single dose of CTLA4-Ig.
“Then we followed her very closely,” says Dr. Aranow. “When patients are involved in research studies, it becomes exceedingly important to find out how they respond and react to a new agent.”
Influence beyond Lupus Care
MAKE AN APPOINTMENT
Know a rheumatologist or rheumatology health professional to whom we should pay an “Office Visit”? Send your suggestion to the editors via e-mail at: [email protected].
Dr. Aranow’s influence has been nothing short of profound, in Ramona’ assessment. “[Dr. Aranow’s] helped me so much that now I work full time,” says Ramona, shyly bragging that she works for the dean of a community college. “I just graduated and got my associate’s in computer information technology, and this would never have happened if I didn’t have a doctor that helped me get through all this.”
* The patient’s name has been changed.
Lola Butcher is a medical journalist based in Missouri.
